Featured Product

Benefits of Freeze-dried Live Attenuated Hepatitis A Vaccine:

• The vaccine virus strains are screened from the hepatitis A epidemic strains of China, with quite stable genome and registered in the international gene pool
• A hepatitis A vaccine type recommended by the World Health Organization (WHO)
• A highly purified virus vaccine, without human albumin or any other harmful additive
• Results of 25 years of use scientifically prove that
     ——The vaccine is quite safe, without vaccine reactions clinically, or vaccine associated cases reported
     ——The vaccine is quite effective: the results of 25 years of testing prove that the vaccinees are ensured to have a high titer of neutralizing antibody, and persistent existence of T cell and B cell immune recall responses, showing that this vaccine has quite lasting immune protection effect.
• This vaccine has been exported to the international market (implementing the European Pharmacopoeia standards) for over a decade, and there is a published paper on the effect after 10 years of use that proves its safety and effectiveness
• It is recommended by Indian Academy of Pediatrics
• The dosage is changed from 1.0ml to 0.5ml, to reduce pain of children
• The duration of validity of the vaccine is extended from 18 months to 24 months, and the vaccine has stable quality and is convenient for use
• There are relevant complete Phase I, II, III, and IV clinical reports (China), and the relevant Phase III clinical report (India) was published on an authoritative journal

International Market

Freeze-dried Live Attenuated Hepatitis A Vaccine has been proved to have good safety and immune protection effect through over 10 years of popularization and application, and is particularly suitable for the applications, and prevention and control of hepatitis A in developing countries. This vaccine received the import approval and market registration approval of the Indian drug administration in 2005, and the first batch of this vaccine was formally exported to India in January 2006, being the first vaccine with independent intellectual property that was formally exported to the international market after international standard demonstration. Then, this vaccine has been successively exported to numerous countries such as Uzbekistan, Philippines, and Guatemala, and is now being actively registered and conducted clinical trial in Russia, Chile, Southeast Asian countries, and African countries.

About the Company

As a company specialized in exporting biological vaccines and biological preparations, Shenzhen Mellow Hope Pharm Industrial Co., Ltd (hereinafter referred to as “Mellow Hope”) has developed into one of the largest Chinese exporters of biological vaccines, bio pharma products and biological preparations through over a decade of unremitting efforts. The export of human vaccines reached USD 33.24 million in China in the first half of 2016, and as a major export enterprise therein, Mellow Hope accounted for 89.5% of the total export amount of human vaccines in China together with Chengdu Institute of Biological Products.

Mellow Hope has increased the blood product and medical device plates in recent years, besides the vaccine and biological preparation products; and it continues to enhance reputation and establish huge sales network in Eastern Europe, South Asia, Southeast Asia, Central Asia, Latin America, and Africa, etc. through cooperating with Chinese biology institutes and enterprises as well as international leading biology institutions, and using effective marketing modes such as cooperation with doctors and hospitals as well as academic exchanges, and will become a world famous biopharmaceutical group in 3-5 years.

Date: November 14, 2017 By Felicia